{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:34:17Z","timestamp":1775054057263,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,3]],"date-time":"2017-09-03T00:00:00Z","timestamp":1504396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bjhh.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T20:00:14Z","timestamp":1505246414000},"page":"337-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Reactions related to asparaginase infusion in a 10-year retrospective cohort"],"prefix":"10.1016","volume":"39","author":[{"given":"Amanda Cabral dos","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Gerardin Poirot","family":"Land","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalia Peroni da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly Oliveira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisangela da Costa","family":"Lima-Dellamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjhh.2017.08.002_bib0145","series-title":"Epidemiologia dos tumores da crian\u00e7a e do adolescente [Internet]","author":"Instituto Nacional do C\u00e2ncer","year":"2015"},{"issue":"2","key":"10.1016\/j.bjhh.2017.08.002_bib0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of l-asparaginase in childhood ALL","volume":"28","author":"M\u00fcller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.bjhh.2017.08.002_bib0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.002_bib0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"Van der Sluis","year":"2016","journal-title":"Haematogica"},{"issue":"8","key":"10.1016\/j.bjhh.2017.08.002_bib0165","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0170","series-title":"Drug allergies [Internet]","author":"World Allergy Organization","year":"2017"},{"issue":"10","key":"10.1016\/j.bjhh.2017.08.002_bib0175","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00228-013-1546-0","article-title":"Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer","volume":"69","author":"Ruggiero","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.002_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e32831961b3","article-title":"Hypersensitivity reactions to antineoplastic agents: an overview","volume":"20","author":"Syrigou","year":"2009","journal-title":"AntiCancer Drugs"},{"issue":"2","key":"10.1016\/j.bjhh.2017.08.002_bib0185","first-page":"42","article-title":"Rea\u00e7\u00f5es de hipersensibilidade a medicamentos","volume":"32","author":"Ensina","year":"2009","journal-title":"Rev Bras Alergimunopatol"},{"issue":"16","key":"10.1016\/j.bjhh.2017.08.002_bib0190","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2217\/fon.14.138","article-title":"How to manage asparaginase hipersensitivity in acute lymphoblastic leukemia","volume":"10","author":"Burke","year":"2014","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.002_bib0195","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1200\/JCO.2013.48.6522","article-title":"Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002","volume":"32","author":"Stary","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bjhh.2017.08.002_bib0200","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2217\/fon-2016-0005","article-title":"Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leucemia","volume":"12","author":"Asselin","year":"2016","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.bjhh.2017.08.002_bib0205","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of l-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bjhh.2017.08.002_bib0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0215","series-title":"ALL IC-BFM 2009. A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia [Internet]","author":"Campbell","year":"2016"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0220","series-title":"Sistema de informa\u00e7\u00f5es ambulatoriais: manual de bases t\u00e9cnicas [Internet]","author":"Minist\u00e9rio da Sa\u00fade","year":"2017"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0225","article-title":"Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with l-asparaginase in children with acute lymphoblastic leukemia [Internet]","author":"Czogala","year":"2014","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.bjhh.2017.08.002_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.002_bib0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1590\/S1516-44462000000300008","article-title":"Intera\u00e7\u00e3o medicamentosa de venlafaxina com captopril","volume":"22","author":"Sucar","year":"2000","journal-title":"Rev Bras de Psiquiatr"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0240","series-title":"Avoiding adverse drug reactions in children \u2013 development of the liverpool adverse drug reaction avoidability assessment tool","first-page":"23","author":"Bracken","year":"2015"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0245","series-title":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE) [Internet]","author":"Nacional Cancer Institute (NCI)","year":"2006"},{"issue":"7","key":"10.1016\/j.bjhh.2017.08.002_bib0250","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impacttreatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bjhh.2017.08.002_bib0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1043454212471728","article-title":"Managing hipersensitivity to asparaginase in pediatrics, adolescents, and young adults","volume":"30","author":"Shinnick","year":"2013","journal-title":"J Pediatr Oncol Nurs"},{"issue":"1","key":"10.1016\/j.bjhh.2017.08.002_bib0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08880018.2010.484852","article-title":"Transient hyperammonemia due to l-asparaginase therapy in children with acute lymphoblastic leukemia or non-hodgkin lymphoma","volume":"28","author":"Jorck","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bjhh.2017.08.002_bib0265","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/pbc.26123","article-title":"Alergic-like reactions to asparaginase: atypical allergies without asparaginase inactivation","volume":"63","author":"Kloss","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.bjhh.2017.08.002_bib0270","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/leu.2012.102","article-title":"Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia","volume":"26","author":"Liu","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bjhh.2017.08.002_bib0275","series-title":"Pediatric clinical pharmacology","first-page":"205","author":"Seybert","year":"2011"},{"issue":"3","key":"10.1016\/j.bjhh.2017.08.002_bib0280","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/10428194.2016.1213826","article-title":"Differentiating hypersensitivity versus infusion related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leucemia","volume":"58","author":"Burke","year":"2017","journal-title":"Leuk Lymphoma"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848417301068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848417301068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T07:09:57Z","timestamp":1574838597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848417301068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1516848417301068"],"URL":"https:\/\/doi.org\/10.1016\/j.bjhh.2017.08.002","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactions related to asparaginase infusion in a 10-year retrospective cohort","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Hematologia e Hemoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjhh.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Editora Ltda. on behalf of Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular.","name":"copyright","label":"Copyright"}]}}